Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on developing one-time curative genetic therapies, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's President and CEO, Keith Gottesdiener, M.D., will engage in a fireside chat on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA.
The presentation will be accessible through a live audio webcast in the 'Events & Presentations' section of Prime Medicine's website. Interested parties can access the replay of the webcast on the company's website for 30 days after the presentation.
Prime Medicine (Nasdaq: PRME), un'azienda biotecnologica focalizzata nello sviluppo di terapie genetiche curative una tantum, ha annunciato la sua partecipazione al 45° Annual Health Care Conference di TD Cowen. Il Presidente e CEO dell'azienda, Keith Gottesdiener, M.D., parteciperà a un colloquio informale il lunedì 3 marzo 2025, alle 11:10 ET a Boston, MA.
La presentazione sarà accessibile tramite una diretta audio sul sito web di Prime Medicine, nella sezione 'Eventi e Presentazioni'. Le parti interessate potranno accedere alla registrazione della diretta sul sito dell'azienda per 30 giorni dopo la presentazione.
Prime Medicine (Nasdaq: PRME), una empresa biotecnológica centrada en el desarrollo de terapias genéticas curativas de una sola vez, ha anunciado su participación en la 45ª Conferencia Anual de Atención Médica de TD Cowen. El presidente y CEO de la empresa, Keith Gottesdiener, M.D., participará en una charla informal el lunes 3 de marzo de 2025, a las 11:10 a.m. ET en Boston, MA.
La presentación estará disponible a través de una transmisión de audio en vivo en la sección 'Eventos y Presentaciones' del sitio web de Prime Medicine. Las partes interesadas podrán acceder a la grabación de la transmisión en el sitio web de la empresa durante 30 días después de la presentación.
프라임 메디슨 (Nasdaq: PRME)은 일회성 치유 유전자 치료 개발에 중점을 둔 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Keith Gottesdiener, M.D.는 2025년 3월 3일 월요일 오전 11시 10분 ET에 매사추세츠주 보스턴에서 화상 대화에 참여할 예정입니다.
발표는 프라임 메디슨 웹사이트의 '이벤트 및 발표' 섹션을 통해 실시간 오디오 웹캐스트로 접근할 수 있습니다. 관심 있는 분들은 발표 후 30일 동안 회사 웹사이트에서 웹캐스트의 재생을 이용할 수 있습니다.
Prime Medicine (Nasdaq: PRME), une entreprise de biotechnologie axée sur le développement de thérapies géniques curatives à usage unique, a annoncé sa participation à la 45e Conférence Annuelle sur les Soins de Santé de TD Cowen. Le président et PDG de l'entreprise, Keith Gottesdiener, M.D., participera à une discussion informelle le lundi 3 mars 2025, à 11h10 ET à Boston, MA.
La présentation sera accessible via un webinaire audio en direct dans la section 'Événements & Présentations' du site web de Prime Medicine. Les parties intéressées pourront accéder à la rediffusion du webinaire sur le site de l'entreprise pendant 30 jours après la présentation.
Prime Medicine (Nasdaq: PRME), ein biotechnologisches Unternehmen, das sich auf die Entwicklung einmaliger heilender Gentherapien konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Der Präsident und CEO des Unternehmens, Keith Gottesdiener, M.D., wird am Montag, den 3. März 2025, um 11:10 Uhr ET in Boston, MA, an einem informellen Gespräch teilnehmen.
Die Präsentation wird über einen Live-Audio-Webcast im Bereich 'Veranstaltungen & Präsentationen' der Website von Prime Medicine zugänglich sein. Interessierte Parteien können die Wiederholung des Webcasts 30 Tage nach der Präsentation auf der Website des Unternehmens abrufen.
- None.
- None.
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA.
A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology and oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor Contact
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
FAQ
When is Prime Medicine (PRME) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Prime Medicine's (PRME) TD Cowen Conference presentation?
How long will Prime Medicine's (PRME) TD Cowen Conference presentation be available for replay?
Who will represent Prime Medicine (PRME) at the TD Cowen Healthcare Conference 2025?
